Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last day of ASCO 2019. MacroGenics' trial compared its margetuximab candida
Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. One such story at ASCO 2019 was the data on Amgen’s KRAS
Exclusive live coverage from day five of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, prod
At ASCO, a lot of attention is given to the results of the large, clinical practices changing phase III studies, but the future is also here. Early phase I and II trials that test
Sanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 candidate isatuximab in multiple myeloma, already filed in the US and Europe. Headl
